pembrolizumab
merck
['gyn', 'keynote-826']
#asco23 update: prof. from shared the most noteworthy information from the recent oral abstract session. among the highlights were the final overall survival results of the keynote-826 phase 3 study. watch the video at #gynaeco 
MediMix, your communication partner with a focus on quality information in easy consumable formats, tailor-made for medical specialists.